Landos Biopharma, Inc. Quarterly Return On Equity in % from Q3 2021 to Q1 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Landos Biopharma, Inc. quarterly/annual Return On Equity history and growth rate from Q3 2021 to Q1 2024.
  • Landos Biopharma, Inc. Return On Equity for the quarter ending March 31, 2024 was -73 %, a 8.91% decline year-over-year.
  • Landos Biopharma, Inc. annual Return On Equity for 2023 was -54.9 %, a 31.2% increase from 2022.
  • Landos Biopharma, Inc. annual Return On Equity for 2022 was -79.8 %, a 95.8% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q1 2024 -73 -5.97 -8.91% Jan 1, 2024 Mar 31, 2024
Q4 2023 -54.9 +24.9 +31.2% Oct 1, 2023 Dec 31, 2023
Q3 2023 -50.4 +42.2 +45.6% Jul 1, 2023 Sep 30, 2023
Q2 2023 -53.2 +29.7 +35.8% Apr 1, 2023 Jun 30, 2023
Q1 2023 -67 -15.6 -30.3% Jan 1, 2023 Mar 31, 2023
Q4 2022 -79.8 -39.1 -95.8% Oct 1, 2022 Dec 31, 2022
Q3 2022 -92.6 -44.5 -92.5% Jul 1, 2022 Sep 30, 2022
Q2 2022 -82.9 Apr 1, 2022 Jun 30, 2022
Q1 2022 -51.5 Jan 1, 2022 Mar 31, 2022
Q4 2021 -40.8 Oct 1, 2021 Dec 31, 2021
Q3 2021 -48.1 Jul 1, 2021 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.